A study published in Stroke evaluates the therapeutic potential of human stem cell-derived extracellular vesicles (NSC EVs) in a large animal model representative of the human brain.
According to ArunA Biomedical, the study results suggest that the NSC EV treatment was neuroprotective, eliminated intracranial hemorrhage in ischemic lesions, improved behavior and mobility, decreased cerebral infarct volume and brain swelling, and led to significant improvements at the tissue and functional levels.
“This study, coupled with our previously published studies focused on a mouse model, represents the first time that a company demonstrated proof-of-concept of the therapeutic potential of extracellular vesicles in two divergent animal species and two stroke types—embolic and ischemic,” says Steven Stice, PhD, co-founder, chief executive and chief scientific officer of Athens, Ga-based ArunA Biomedical, who led the study with the Regenerative Bioscience Center at the University of Georgia, in a media release.
“Like the human brain, the pig brain contains more than 60 percent white matter, the tissue most vulnerable to pathological processes that follow ischemic stroke. This compares to the rodent brain containing approximately 10 percent white matter. These results represent a significant step in our plan to develop a new, cell-free treatment for stroke,” Stice continues.
[Source(s): ArunA Biomedical, Business Wire]
